Pfizer

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Pfizer and other ETFs, options, and stocks.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
83,000
Employees83,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
83,000
Employees83,000

PFE Key Statistics

Market cap
229.34B
Market cap229.34B
Price-Earnings ratio
7.33
Price-Earnings ratio7.33
Dividend yield
4.01%
Dividend yield4.01%
Average volume
26.96M
Average volume26.96M
High today
$40.95
High today$40.95
Low today
$40.94
Low today$40.94
Open price
$40.13
Open price$40.13
Volume
10.38K
Volume10.38K
52 Week high
$56.32
52 Week high$56.32
52 Week low
$39.23
52 Week low$39.23

PFE News

Yahoo Finance 14h
Pfizer Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

In the latest trading session, Pfizer (PFE) closed at $40.81, marking a +1.77% move from the previous day. This change outpaced the S&P 500's 0.89% gain on the...

Pfizer Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Benzinga 16h
Insiders Selling Pfizer And 2 Other Stocks

The Nasdaq Composite traded slightly higher on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it indicates th...

Insiders Selling Pfizer And 2 Other Stocks
Simply Wall St 1d
Insiders at Pfizer Inc. sold US$7.6m worth of stock, possibly indicating weakness in the future - Simply Wall St

Over the past year, many Pfizer Inc. ( ) insiders sold a significant stake in the company which may have piqued investors' interest. When evaluating insider tra...

Insiders at Pfizer Inc. sold US$7.6m worth of stock, possibly indicating weakness in the future - Simply Wall St

Analyst ratings

59%

of 22 ratings
Buy
40.9%
Hold
59.1%
Sell
0%

PFE Earnings

$0.00
$0.68
$1.36
$2.04
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Q1 FY23
Estimated
per share
Estimated per share
Actual
Expected May 2, Pre-Market
ActualExpected May 2, Pre-Market

More PFE News

Yahoo Finance 4d
Pfizer's COVID-19 Drug Paxlovid Gets FDA Panel Vote - Yahoo Finance

Pfizer, Inc. PFE announced that the FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) voted 16 to 1 in favor of Paxlovid for the treatment of mild-to-moderat...

Pfizer's COVID-19 Drug Paxlovid Gets FDA Panel Vote - Yahoo Finance
Benzinga 4d
Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug

https://cdn.benzinga.com/files/images/story/2023/03/17/pfe.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Pfizer Inc (NYSE: PFE) and Astellas Pharma Inc (...

Pfizer, Astellas Tout Positive Xtandi Data To Potentially Expand Label For The Prostate Cancer Drug
Yahoo Finance 4d
FDA Advisory Committee Votes Favoring Pfizer's COVID-19 Pill ... - Yahoo Finance

https://cdn.benzinga.com/files/images/story/2023/03/17/paxlovid.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 The FDA's Antimicrobial Drugs Advisory Comm...

FDA Advisory Committee Votes Favoring Pfizer's COVID-19 Pill ... - Yahoo Finance
Yahoo Finance 4d
Pfizer Working To Develop New Packaging For Migraine Drug Over ... - Yahoo Finance

https://cdn.benzinga.com/files/images/story/2023/03/17/pfizer_finland_hq_february_13_2009.jpg?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Pfizer Inc (NYSE:...

Pfizer Working To Develop New Packaging For Migraine Drug Over ... - Yahoo Finance
Yahoo Finance 4d
Pharma Stock Roundup: M&A Boom in Drug Industry With PFE ... - Yahoo Finance

This week, M&A activity picked up momentum in the drug and biotech sector, with Pfizer PFE announcing a huge $43 billion offer for another cancer drugmaker, Sea...

Pharma Stock Roundup: M&A Boom in Drug Industry With PFE ... - Yahoo Finance
Yahoo Finance 5d
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer's PAXLOVID™ - Yahoo Finance

The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is May 2023 NEW YORK, March 16, 2023--(BUSINESS WIRE)--Pfizer Inc. (NYS...

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer's PAXLOVID™ - Yahoo Finance
MarketWatch 5d
FDA committee says benefits outweigh risks for Pfizer’s Paxlovid

A Food and Drug Administration advisory committee voted 16-1 that the benefits of Pfizer’s PFE COVID antiviral Paxlovid outweigh the risks in adults who are at...

FDA committee says benefits outweigh risks for Pfizer’s Paxlovid
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.